Precision Dosing in Clinical Therapeutics: The Application of Pharmacokinetics and Pharmacometrics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 10 November 2024 | Viewed by 1806

Special Issue Editor

Aston Pharmacy School, College of Health and Life Sciences, Aston University, Birmingham B4 7ET, UK
Interests: pharmacokinetics; PBPK; drug metabolism; drug-drug interactions; modelling and simulation; clinical pharmacy; medicines optimization

Special Issue Information

Dear Colleagues,

I am delighted to announce a Special Issue in Pharmaceutics, titled "Precision Dosing in Clinical Therapeutics: The Application of Pharmacokinetics and Pharmacometrics". As the Guest Editor, I invite academics specialising in pharmacokinetics to contribute their cutting-edge research to this pivotal edition.

Precision dosing has emerged as a cornerstone in optimising therapeutic outcomes and minimising adverse effects. This Special Issue provides a dedicated platform to showcase advancements in the application of pharmacokinetics and pharmacometrics, unravelling the intricacies of drug disposition and clinical response.

We welcome submissions that explore novel methodologies, technological innovations, and integrative approaches in precision dosing. Whether it be population pharmacokinetics, model-informed precision dosing, or the utilisation of real-world data, we encourage contributions that push the boundaries of knowledge in this critical field.

The goal of this Special Issue is to showcase strong examples of successfully applied pharmacokinetic modelling approaches that support precision dosing and highlight the present status quo and future perspectives of this technology in the field of pharmacometrics.

We look forward to receiving your contributions.

Dr. Raj Badhan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pharmacometrics
  • PBPK
  • drug–drug interactions
  • pediatrics
  • pregnancy
  • oral bioavailability
  • modelling and simulation
  • population pharmacokinetics

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3464 KiB  
Article
Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients Using Population Pharmacokinetics and Monte Carlo Simulation
by Yong-Kyun Kim, Kyeong-Min Jo, Jae-Ha Lee, Ji-Hoon Jang, Eun-Jun Choe, Gaeun Kang, Dae-Young Zang and Dong-Hwan Lee
Pharmaceutics 2024, 16(4), 499; https://doi.org/10.3390/pharmaceutics16040499 - 5 Apr 2024
Viewed by 693
Abstract
In patients with normal renal function, significant teicoplanin dose adjustments are often necessary. This study aimed to develop a population pharmacokinetic (PK) model for teicoplanin in healthy adults and use it to recommend optimal dosage regimens for patients with normal renal function. PK [...] Read more.
In patients with normal renal function, significant teicoplanin dose adjustments are often necessary. This study aimed to develop a population pharmacokinetic (PK) model for teicoplanin in healthy adults and use it to recommend optimal dosage regimens for patients with normal renal function. PK samples were obtained from 12 subjects and analyzed using a population approach. The derived parameters informed Monte Carlo simulations for dosing recommendations. The PK profile was best described using a three-compartment model, in which the estimated glomerular filtration rate calculated via the CKD-EPI equation and adjusted for body surface area was identified as a significant covariate affecting total clearance. For pathogens with a minimum inhibitory concentration of 1 mg/L, a loading dose (LD) of 14 mg/kg administered every 12 h for four doses, followed by a maintenance dose (MD) of 16 mg/kg administered every 24 h, is recommended. These findings indicate the need for dosage adjustments, such as increasing the LD and MD or decreasing the dosing interval of MD in patients with normal renal function. Because of the long half-life of teicoplanin and the requirement for long-term administration, therapeutic drug monitoring at strategic intervals is important to avoid nephrotoxicity associated with elevated trough concentrations. Full article
Show Figures

Figure 1

30 pages, 6228 KiB  
Article
The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine
by Khairulanwar Burhanuddin, Afzal Mohammed and Raj K. S. Badhan
Pharmaceutics 2024, 16(4), 489; https://doi.org/10.3390/pharmaceutics16040489 - 2 Apr 2024
Viewed by 892
Abstract
The incidence of paediatric obesity continues to rise worldwide and contributes to a range of diseases including cardiovascular disease. Obesity in children has been shown to impact upon the plasma concentrations of various compounds, including amlodipine. Nonetheless, information on the influence of obesity [...] Read more.
The incidence of paediatric obesity continues to rise worldwide and contributes to a range of diseases including cardiovascular disease. Obesity in children has been shown to impact upon the plasma concentrations of various compounds, including amlodipine. Nonetheless, information on the influence of obesity on amlodipine pharmacokinetics and the need for dose adjustment has not been studied previously. This study applied the physiologically based pharmacokinetic modelling and established a paediatric obesity population to assess the impact of obesity on amlodipine pharmacokinetics in children and explore the possible dose adjustments required to reach the same plasma concentration as non-obese paediatrics. The difference in predicted maximum concentration (Cmax) and area under the curve (AUC) were significant between children with and without obesity across the age group 2 to 18 years old when a fixed-dose regimen was used. On the contrary, a weight-based dose regimen showed no difference in Cmax between obese and non-obese from 2 to 9 years old. Thus, when a fixed-dose regimen is to be administered, a 1.25- to 1.5-fold increase in dose is required in obese children to achieve the same Cmax concentration as non-obese children, specifically for children aged 5 years and above. Full article
Show Figures

Figure 1

Back to TopTop